SML4101

TMP269

≥98% (HPLC)

• Synonym(s): N-((4-(4-Phenylthiazol-2-yl)tetrahydro-2H-pyran-4-yl)methyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide, TMP 269, TMP-269
• Empirical Formula (Hill Notation): C₂₅H₂₁F₃N₄O₃S
• CAS Number: 1314890-29-3
• Molecular Weight: 514.52
• UNSPSC Code: 12352200

Properties

• Quality Level: 100
• Assay: ≥98% (HPLC)
• form: powder
• color: white to yellow-orange
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: -10 to -25°C

Description

Biochem/physiol Actions

Potent and type IIa-selective histone deacetylases (HDAC4/5/7/9) inhibitor in vitro and in vivo.



TMP269 is a potent and type IIa-selective histone deacetylases (HDACs) inhibitor (HDAC4/5/7/9 Ki = 126/80/36/19 nM, IC50 = 157/97/43/23 nM; HDAC6/8 IC50 = 8.2/4.2 μM, HADC1/2/3/10/11 IC50 >100 μM) with an active site zinc-targeting trifluoromethyloxadiazole (TFMO). TMP269 inhibits the growth of AsPC-1 by upregulating FOXO3a expression and displays in vivo therapeutic efficacy in animal models of acute kidney injury (50 mg/kg via i.p. in mice) and cerebral ischemia/reperfusion injury (1-16 mg/kg via i.p. in rats).